Big Pharma | The Gillett Health Podcast #34
The Gillett Health Podcast
The Heterogeneity of Compounding Pharmacies
A lot of the trials for vasoactive intestinal peptide and it's a bit different for this they're looking for. I believe late in 2022, it received its not emergency use authorization but it received its fast track to be a drug for Disney fast pass. So you can slice and dice the data a million different ways. There's a lot of heterogeneity with compounding pharmacies. And there's another potential polyfill VIP with migraine bed. You combine the nasal sprays. This is true. The one that described itself as a phase two B slash three trial. Not sure exactly why, but we thought we'd take note of that. Is it two B or is it not two B
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
